Search Results - "Nuzzo, F"

The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy by Perrone, F., Jommi, C., Di Maio, M., Gimigliano, A., Gridelli, C., Pignata, S., Ciardiello, F., Nuzzo, F., de Matteis, A., Del Mastro, L., Bryce, J., Daniele, G., Morabito, A., Piccirillo, M.C., Rocco, G., Guizzaro, L., Gallo, C.

“…Financial difficulties, measured by the EORTC C30 questionnaire, were associated with worse quality of life and shorter overall survival of cancer patients…”
Get full text

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial by Perrone, F., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Labonia, V., Landi, G., Pacilio, C., Rossi, E., De Laurentiis, M., D'Aiuto, M., Botti, G., Forestieri, V., Lauria, R., De Placido, S., Tinessa, V., Daniele, B., Gori, S., Colantuoni, G., Barni, S., Riccardi, F., De Maio, E., Montanino, A., Morabito, A., Daniele, G., Di Maio, M., Piccirillo, M.C., Signoriello, S., Gallo, C., de Matteis, A.

“…Evidence on adjuvant chemotherapy for elderly early breast cancer patients is poor, due to the low number of phase 3 trials. ELDA shows that weekly docetaxel…”
Get full text

Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency by Nuzzo, F., Bulato, C., Nielsen, B. I., Lee, K., Wielders, S. J., Simioni, P., Key, N. S., Castoldi, E.

“…Summary Coagulation factor V (FV) deficiency is a rare autosomal recessive bleeding disorder. We investigated a patient with severe FV deficiency (FV:C < 3%)…”
Get full text

The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid by Perrone, F., De Laurentiis, M., de Placido, S., Orditura, M., Cinieri, S., Riccardi, F., Ribecco, A.S., Putzu, C., Del Mastro, L., Rossi, E., Daniele, B., Mosconi, A.M., Di Rella, F., Landi, G., Nuzzo, F., Pacilio, C., Lauria, R., Arenare, L., Piccirillo, M.C., Gallo, C.

Get full text

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials by Arenare, L., Di Liello, R., De Placido, P., Gridelli, C., Morabito, A., Pignata, S., Nuzzo, F., Avallone, A., Maiello, E., Gargiulo, P., Schettino, C., Gravina, A., Gallo, C., Chiodini, P., Di Maio, M., Perrone, F., Piccirillo, M.C.

“…Oncologists tend to under-report subjective symptoms during cancer treatment. This study describes the under-reporting rate of selected symptoms and explores…”
Get full text

Identification of a novel large deletion in a patient with severe factor V deficiency using an in-house F5 MLPA assay by Nuzzo, F., Paraboschi, E. M., Straniero, L., Pavlova, A., Duga, S., Castoldi, E.

“…Summary Factor V (FV) deficiency is a rare autosomal recessive bleeding disorder caused by mutations in the F5 gene. FV‐deficient patients in whom no mutation…”
Get full text

PerTe: efficacy and safety of pertuzumab in "real life setting" for the neoadjuvant treatment of HER2-positive breast cancer patients by Cianniello, D, Prudente, A, Caputo, R, Piezzo, M, Riemma, M, Savastano, B, Cocco, S, Licenziato, M, De Stefano, B, Di Gioia, G, Fusco, G, Buonfanti, G, Gravina, A, Landi, G, Di Rella, F, Pacilio, C, Nuzzo, F, Iodice, G, De Laurentiis, M, Del Prete, S

Get full text

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial by De Placido, S., Gallo, C., De Laurentiis, M., Bisagni, G., Arpino, G., Sarobba, M.G., Riccardi, F., Russo, A., Del Mastro, L., Cogoni, A., Cognetti, F., Gori, S., Frassoldati, A., Amoroso, D., Laudadio, L., Moscetti, L., Montemurro, F., Nuzzo, F., Carlini, P., Perrone, F.

Get full text

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study by Nuzzo, F., Gallo, C., Lastoria, S., Di Maio, M., Piccirillo, M.C., Gravina, A., Landi, G., Rossi, E., Pacilio, C., Labonia, V., Di Rella, F., Bartiromo, A., Buonfanti, G., De Feo, G., Esposito, G., D'Aniello, R., Maiolino, P., Signoriello, S., De Maio, E., Tinessa, V., Colantuoni, G., De Laurentiis, M., D'Aiuto, M., Di Bonito, M., Botti, G., Giordano, P., Daniele, G., Morabito, A., Normanno, N., de Matteis, A., Perrone, F.

“…To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid. A phase 3…”
Get full text

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer by Bisagni, G., Musolino, A., Panebianco, M., De Matteis, A., Nuzzo, F., Ardizzoni, A., Gori, S., Gamucci, T., Passalacqua, R., Gnoni, R., Moretti, G., Boni, C.

“…Background Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and…”
Get full text

What It Takes: Perspectives From Developing Nurse Scientists by Hill, Nikki L., Yevchak, Andrea, Kolanowski, Ann M., Penrod, Janice, Milone-Nuzzo, Paula F., Sawyer, Amy M., Metzger, Bonnie, Therrien, Barbara

“…The need for nurse scientists has never been greater, given the complexity of health problems facing our world and the rising cost of providing care to prevent…”
Get full text

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial by PACILIO, C, MORABITO, A, BOTTI, G, NORMANNO, N, CHIODINI, P, GALLO, C, PERRONE, F, DE MATTEIS, A, NUZZO, F, GRAVINA, A, LABONIA, V, LANDI, G, ROSSI, E, DE MAIO, E, DI MAIO, M, D'AIUTO, G

“…The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer…”
Get full text

Meta-analysis applied to operations management: Summarizing the results of empirical research by Forza, C., Di Nuzzo, F.

“…The writing of every new management study should include an enquiry into previous, related investigations. This approach helps to build up a comprehensive…”
Get full text

5047 Effects on quality of life (QoL) of docetaxel-based weekly chemotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC): results of a single-centre randomized phase 3 trial by Nuzzo, F, Rella, F. Di, Morabito, A, Gravina, A, Labonia, V, Landi, G, Pacilio, C, Piccirillo, M.C, Maio, M. Di, de Matteis, A

Get full text

449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study by von Arx, C., Calabrese, A., Martinelli, C., Di Lauro, V., Grimaldi, V., Pensabene, M., Caputo, R., Cerillo, I., Cianniello, D., Buono, G., Verrazzo, A., Pacilio, C., Di Rella, F., Nuzzo, F., De Laurentiis, M.

Get full text

Intestinal side-effects of docetaxel/vinorelbine combination by de Matteis, Andrea, Nuzzo, Francesco, Rossi, Emanuela, Landi, Gabriella, Perrone, Francesco

Get full text

2034 POSTER Weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial by Nuzzo, F, Perrone, F, Labonia, V, Pacilio, C, Gravina, A, D'Aiuto, G, Signoriello, G, Landi, G, Piccirillo, M.C, de Matteis, A

Get full text

An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients by Pacilio, Carmen, Rosati, Gerardo, Crispo, Anna, Bimonte, Sabrina, DI Rella, Francesca, Nuzzo, Francesco, DE Laurentiis, Michelino

“…Breast cancer is the most common type of cancer in women worldwide. Many studies indicate that breast cancer increases in elderly patients (≥70 years) and…”
Get full text

Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse by Tampellini, M, Berruti, A, Gorzegno, G, Bitossi, R, Bottini, A, Durando, A, De Matteis, A, Farris, A, Donadio, M, De Fabiani, E, Manzin, E, Arese, P, Sarobba, M G, Castiglione, F, Moro, G, Bonazzi, G, Nuzzo, F, Massobrio, M, Dogliotti, L

“…Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients…”
Get more information

Corrigendum to “Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials” by Arenare, L., Di Liello, R., De Placido, P., Gridelli, C., Morabito, A., Pignata, S., Nuzzo, F., Avallone, A., Maiello, E., Gargiulo, P., Schettino, C., Gravina, A., Gallo, C., Chiodini, P., Di Maio, M., Perrone, F., Piccirillo, M.C.

Get full text